Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...
If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.
More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.
Bayer representatives with leaders from CU Anschutz, UCHealth, and Children’s Hospital Colorado. Credit: University of Colorado Anschutz / PRNewswire. Bayer has entered a strategic alliance with the ...
Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...
The pivotal cohort enrolled 136 participants aged two to below 18 years, all with AS and genetically confirmed UBE3A mutation. Credit: Shidlovski / Shutterstock.com. Ionis Pharmaceuticals has ...
Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection.
MP0712 targets the tumour-associated DLL3 protein in over 85% of SCLC tumours. Credit: bangoland / Shutterstock.com. Molecular Partners and Orano Med have dosed the first patient in the Phase I/IIa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results